Screener
Enliven Therapeutics ELVN Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
FAQ
- What is Enliven Therapeutics's return on equity?
- Enliven Therapeutics (ELVN) reported return on equity of -26.6% in Q1 2026.
- How has Enliven Therapeutics's return on equity changed year-over-year?
- Enliven Therapeutics's return on equity increased by 14.9% year-over-year, from -31.3% to -26.6%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Enliven Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude